A patient (46XX) with congenital adrenal hyperplasia and prostate cancer: A case report

Ruben Wesselius; Mirjam Schotman; Martje Schotman; Alberto M. Pereira

doi:10.1210/js.2017-00281

A patient (46XX) with congenital adrenal hyperplasia and prostate cancer: A case report

Ruben Wesselius^*
, Mirjam Schotman
, Martje Schotman
, Alberto M. Pereira

^*Corresponding author for this work

Department of Urology
Meander Medical Center
Department of Urology
Leiden University
Department of Medicine

Research output: Contribution to journal › Article › Academic › peer-review

6 Downloads (Pure)

Abstract

Congenital adrenal hyperplasia (CAH) can affect sex characteristics. The most common cause of CAH is 21-hydroxylase deficiency, and the cornerstone of treatment is glucocorticoid replacement in adrenocorticotropic hormone-suppressive dosages. A 64-year-old patient (46XX) with CAH resulting from 21- hydroxylase deficiency had been treated with dexamethasone and testosterone since diagnosis at age 12 and was phenotypically male. At age 62, he was diagnosed with prostate carcinoma. The patient received curative treatment with external beam radiotherapy. Genotypically female patients with CAH can develop prostate carcinoma when receiving long-term testosterone replacement therapy.

Original language	English
Pages (from-to)	1213-1216
Number of pages	4
Journal	Journal of the Endocrine Society
Volume	1
Issue number	9
DOIs	https://doi.org/10.1210/js.2017-00281
Publication status	Published - Sept 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

46XX
CAH
Prostate carcinoma
Testosterone replacement

Access to Document

10.1210/js.2017-00281

A-patient-46xx-with-congenital-adrenal-hyperplasia-and-prostate-cancer.pdfFinal published version, 536 KBLicence: CC BY

Cite this

@article{7a6be646c418419391d2123120c04479,

title = "A patient (46XX) with congenital adrenal hyperplasia and prostate cancer: A case report",

abstract = "Congenital adrenal hyperplasia (CAH) can affect sex characteristics. The most common cause of CAH is 21-hydroxylase deficiency, and the cornerstone of treatment is glucocorticoid replacement in adrenocorticotropic hormone-suppressive dosages. A 64-year-old patient (46XX) with CAH resulting from 21- hydroxylase deficiency had been treated with dexamethasone and testosterone since diagnosis at age 12 and was phenotypically male. At age 62, he was diagnosed with prostate carcinoma. The patient received curative treatment with external beam radiotherapy. Genotypically female patients with CAH can develop prostate carcinoma when receiving long-term testosterone replacement therapy.",

keywords = "46XX, CAH, Prostate carcinoma, Testosterone replacement",

author = "Ruben Wesselius and Mirjam Schotman and Martje Schotman and Pereira, \{Alberto M.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Endocrine Society.",

year = "2017",

month = sep,

doi = "10.1210/js.2017-00281",

language = "English",

volume = "1",

pages = "1213--1216",

journal = "Journal of the Endocrine Society",

issn = "2472-1972",

publisher = "Endocrine Society",

number = "9",

}

TY - JOUR

T1 - A patient (46XX) with congenital adrenal hyperplasia and prostate cancer

T2 - A case report

AU - Wesselius, Ruben

AU - Schotman, Mirjam

AU - Schotman, Martje

AU - Pereira, Alberto M.

PY - 2017/9

Y1 - 2017/9

N2 - Congenital adrenal hyperplasia (CAH) can affect sex characteristics. The most common cause of CAH is 21-hydroxylase deficiency, and the cornerstone of treatment is glucocorticoid replacement in adrenocorticotropic hormone-suppressive dosages. A 64-year-old patient (46XX) with CAH resulting from 21- hydroxylase deficiency had been treated with dexamethasone and testosterone since diagnosis at age 12 and was phenotypically male. At age 62, he was diagnosed with prostate carcinoma. The patient received curative treatment with external beam radiotherapy. Genotypically female patients with CAH can develop prostate carcinoma when receiving long-term testosterone replacement therapy.

AB - Congenital adrenal hyperplasia (CAH) can affect sex characteristics. The most common cause of CAH is 21-hydroxylase deficiency, and the cornerstone of treatment is glucocorticoid replacement in adrenocorticotropic hormone-suppressive dosages. A 64-year-old patient (46XX) with CAH resulting from 21- hydroxylase deficiency had been treated with dexamethasone and testosterone since diagnosis at age 12 and was phenotypically male. At age 62, he was diagnosed with prostate carcinoma. The patient received curative treatment with external beam radiotherapy. Genotypically female patients with CAH can develop prostate carcinoma when receiving long-term testosterone replacement therapy.

KW - 46XX

KW - CAH

KW - Prostate carcinoma

KW - Testosterone replacement

UR - https://www.scopus.com/pages/publications/85077776342

U2 - 10.1210/js.2017-00281

DO - 10.1210/js.2017-00281

M3 - Article

AN - SCOPUS:85077776342

SN - 2472-1972

VL - 1

SP - 1213

EP - 1216

JO - Journal of the Endocrine Society

JF - Journal of the Endocrine Society

IS - 9

ER -

A patient (46XX) with congenital adrenal hyperplasia and prostate cancer: A case report

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this